Is Semaglutide the Same as Wegovy — and Does the Difference Matter?

Same molecule, different licences, why the brand name is not just packaging

Semaglutide was developed by Novo Nordisk and is now available in the UK under three distinct brand names: Wegovy, Ozempic, and Rybelsus. Each is the same molecule at its core, but the licensing, the doses, the delivery format, and the legal indication differ in ways that a prescriber cannot simply overlook.

Ozempic is a once-weekly injection licensed in the UK for type 2 diabetes. Its doses top out at 2 mg and its clinical trials were designed around blood-sugar control, not weight management. The NHS medicines page for semaglutide explains the distinction between these products clearly. Prescribing Ozempic specifically to treat obesity (rather than diabetes) is outside its UK licence, and the MHRA has said GLP-1 medicines should not be used for quick or cosmetic weight loss.

Rybelsus is oral semaglutide, but its tablet strengths (3 mg, 7 mg, 14 mg) are calibrated for diabetes management. It is not the same as the Wegovy tablet, which carries an entirely different dose schedule and a separate UK weight-management licence. If a page or seller conflates Rybelsus with Wegovy tablets, that is a red flag worth noting. A quick check on the GPhC pharmacy register can confirm whether any online source offering semaglutide is operating legitimately, it takes under a minute.

Wegovy, by contrast, was developed and licensed with weight management as its primary purpose. That distinction shapes everything from the dose titration schedule to the clinical monitoring a prescriber applies. If you want to understand whether GLP-1 and semaglutide refer to the same thing, that context is worth reading before a consultation.

What sets Wegovy apart as the weight-management form of semaglutide

Wegovy injection starts at 0.25 mg weekly, escalating through 0.5 mg, 1.0 mg, and 1.7 mg to a standard maintenance dose of 2.4 mg, a schedule designed specifically to minimise gastrointestinal side effects during the adjustment phase. In the STEP 1 trial, adults using semaglutide 2.4 mg alongside lifestyle changes achieved around 15% average body-weight reduction over 68 weeks, as published in the New England Journal of Medicine.

Since then, the licensed dose ceiling has risen. The MHRA approved a 7.2 mg maintenance dose for Wegovy in January 2026, and a dedicated single-dose 7.2 mg pen followed in April 2026, for adults with a BMI of 30 or above. Trials at this higher dose showed around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide at its highest doses. The titration still begins at 0.25 mg; 7.2 mg is the maximum, not the starting point.

Then there is the Wegovy tablet. On 11 June 2026 the MHRA approved oral semaglutide for weight management, the first of its kind in the UK. Its dose ladder runs 1.5 mg, 4 mg, 9 mg, and 25 mg daily, taken first thing in the morning on an empty stomach. No refrigeration needed, which many people find genuinely useful for travel. The Wegovy overview page covers both forms in more detail.

Side effects across all semaglutide weight-management products are predominantly gastrointestinal: nausea, diarrhoea, constipation, and indigestion are the most commonly reported, typically settling as the body adjusts. A prescriber will discuss which form and which dose trajectory suits your circumstances.

The decision this search is really pointing at

Most people who ask whether semaglutide and Wegovy are the same thing are really trying to answer one of two questions: is Wegovy the right treatment for me, or is there another semaglutide product I could or should be using instead?

The honest answer is that the branded name matters because the licence matters. A prescription for Wegovy is not interchangeable with a prescription for Ozempic unless a prescriber has made that clinical decision deliberately. Anyone selling semaglutide for weight loss without specifying the product and its licensed indication is not giving you enough information to make a safe choice. You can read more about how Wegovy and semaglutide relate if you want a deeper breakdown.

It is also worth noting that semaglutide is not the only GLP-1 option for weight management. Tirzepatide (Mounjaro) activates two receptors rather than one and showed greater average weight reduction in the SURMOUNT-5 head-to-head trial. Researchers exploring the peer-reviewed evidence can find a useful starting point in the semaglutide studies indexed on Google Scholar, which covers the breadth of published clinical work. How these medicines compare to other GLP-1 agents such as liraglutide is a separate question worth exploring. For a broader look at licensed weight-loss options currently available, that overview covers the landscape.

If Wegovy is something you want to explore seriously, the right next step is a clinical assessment, not a product search. Our prescribers assess your full medical picture (not just your BMI) before anything is recommended. To see whether Wegovy or another treatment might suit you, you can start your free consultation with the nume team today.